Astha-15 may be the first Ayurvedic drug in
the global market addressing the respiratory disorders associated with the deadly
Covid-19.

The Dalmia Healthcare is set to announce the launch of Astha-15, a polyherbal combination of 15
herbs developed by its research arm Dalmia Centre for Research and Development,
for treatment of mild and moderate Covid patients.

“This is a proud moment for India, our own indigenous
Ayurveda and Dalmia Healthcare Limited –has developed Astha-15 for the effective treatment of respiratory disorders in
Covid patients. “We’re happy to announce that the outcome of the clinical trial
showed that Astha-15 has
significantly reduced the cough and wheezing, improved the respiratory rate and
aid in the speedy recovery of Covid-19 patients with the improvement of quality
of life during the treatment cycle,” said Sanjay Dalmia, Chairman, Dalmia Group
of Companies.

Astha-15 will be made available in the first phase
through prescriptions written for mild and moderate Covid patients undergoing
treatment in Covid Hospitals. Dalmia Healthcare will be applying for
permission/approval of Astha-15 usage
in allopathic hospitals, as per the procedure in each hospital, he said.

Aptly named Astha
or faith, Astha-15 acts as a
bronchodilator, decongestant, anti-inflammatory and lung detoxifier. It helps
in eliminating the infection and regulating the allergic reactions. This has a
specific action on the mucosa of the respiratory tract and the muscular walls
of the lungs that act as the airways. It has an anti-inflammatory effect which
reduces inflammation and congestion inside the lungs. Its continuous use
reduces the damage on the lungs and the muscular walls and brings out a significant
reversal in their dysfunction. All these disorders which have been found in
Covid-19 patients have been confirmed to be treated by Astha-15.

Dalmia Healthcare had earlier sought approval for Astha-15 by conducting a clinical trial
to evaluate the efficacy and safety of poly-herbal combination for the treatment
of Covid-19 along with standard care approved as per AYUSH/ICMR guidelines.
After two successful phases, Phase III trial was conducted on 120 subjects at
multi-centric sites viz. JNUIMSRC, Jaipur, Govt. Medical College & Govt.
General hospital, Srikakulam (Old RIMSGGH) and RGMC & CSMH, Thane by
following the regulatory guidelines of AYUSH and the Informed Consent
Declaration, Insurance Terms and Hospital Ethics Committee approvals which are
registered at DCGI to perform the clinical trial.